Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Healthy
Interventions
DRUG

Erythromycin

200 mg suspension

DRUG

Placebo

200 mg suspension

PROCEDURE

Magnetic Resonance Imaging

An MR enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel.

OTHER

Barium Sulfate Solution

Participants will be given a low concentration of barium sulfate solution (1350 mL) prior to the MRI procedure. Barium sulfate is a radiopaque agent. Radiopaque agents are used to help diagnose certain medical problems. Since radiopaque agents are opaque to (block) x-rays, the areas of the body in which they are localized will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues. The contrast will help the doctor see any special conditions that may exist in that organ or part of the body.

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Mayo Clinic

OTHER

NCT01379183 - Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility | Biotech Hunter | Biotech Hunter